Interkingdom Communication and Regulation of Mucosal Immunity by the Microbiome

Ethridge, Alexander D.; Bazzi, Malak; Lukacs, Nicholas W.; Huffnagle, Gary B.

doi:10.1093/infdis/jiaa748

Cited by 15 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Rashidi and colleagues explored this interaction and identified that the microbial genera, Blautia , was critical in dictating the integrity of the intestinal mucosa, proposing a model of microbe-to-mucosa communication [44]. Certainly, microbes have the capacity to influence the mucosa, particularly via their ability to produce beneficial metabolites such as short chain fatty acids [45]. These compounds are a major energy source for colonocytes, promoting epithelial proliferation and regeneration, whilst also promoting barrier integrity via their influence on tight junction assembly.…”

Section: Mucosal-microbial Cross Talkmentioning

confidence: 99%

Role of mucositis in predicting gut microbiota composition in people with cancer

Scott,

Li,

Wardill

2024

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of review Disruption of the precious ecosystem of micro-organisms that reside in the gut – the gut microbiota – is rapidly emerging as a key driver of adverse side effects/toxicities caused by numerous anti-cancer agents. Although the contribution of the gut microbiota to these toxicities is understood with ever increasing precision, the cause of microbial disruption (dysbiosis) remains poorly understood. Here, we discuss current evidence on the cause(s) of dysbiosis after cancer therapy, positioning breakdown of the intestinal mucosa (mucositis) as a central cause. Recent findings Dysbiosis in people with cancer has historically been attributed to extensive antibiotic use. However, evidence now suggests that certain antibiotics have minimal impacts on the microbiota. Indeed, recent evidence shows that the type of cancer therapy used predicts microbiota composition independently of antibiotics. Given most anti-cancer drugs have modest effects on microbes directly, this suggests that their impact on the gut microenvironment, in particular the mucosa, which is highly vulnerable to cytotoxicity, is a likely cause of dysbiosis. Here, we outline evidence that support this hypothesis, and discuss the associated clinical implications/opportunities. Summary The concept that mucositis dictates microbiota compositions provides two important implications for clinical practice. Firstly, it reiterates the importance of prioritising the development of novel mucoprotectants that preserve mucosal integrity, and indirectly support microbial stability. Secondly, it provides an opportunity to identify dysbiotic events and associated consequences using readily accessible, minimally invasive biomarkers of mucositis such as plasma citrulline.

show abstract

Section: Mucosal-microbial Cross Talkmentioning

confidence: 99%

Role of mucositis in predicting gut microbiota composition in people with cancer

Scott,

Li,

Wardill

2024

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

“…It is an oxylipin, a product of the metabolism of linoleic acid, a type of omega-6 fatty acid, formed through mono- or dioxygenase action. Gut bacteria, such as Enterococcus faecalis and Bifidobacterium spp., encode epoxide hydrolase enzymes capable of generating 12,13-diHOME [ 50 ]. This compound can act on dendritic cells, promoting a Th2-type inflammatory response, with its elevation being related to the development of allergic processes.…”

Section: Functional Products Of the Intestinal Microbiotamentioning

confidence: 99%

Exploring Functional Products and Early-Life Dynamics of Gut Microbiota

Martínez-Martínez,

Lamban-Per,

Lezaun

et al. 2024

Nutrients

View full text Add to dashboard Cite

Research on the microbiome has progressed from identifying specific microbial communities to exploring how these organisms produce and modify metabolites that impact a wide range of health conditions, including gastrointestinal, metabolic, autoimmune, and neurodegenerative diseases. This review provides an overview of the bacteria commonly found in the intestinal tract, focusing on their main functional outputs. We explore biomarkers that not only indicate a well-balanced microbiota but also potential dysbiosis, which could foreshadow susceptibility to future health conditions. Additionally, it discusses the establishment of the microbiota during the early years of life, examining factors such as gestational age at birth, type of delivery, antibiotic intake, and genetic and environmental influences. Through a comprehensive analysis of current research, this article aims to enhance our understanding of the microbiota’s foundational development and its long-term implications for health and disease management.

show abstract

“…TJs comprise junctional adhesion molecules, claudins, occludins, and zonula occludens proteins. Some microbial metabolites can modulate the expression of TJs, for instance, SCFAs, prostaglandins, uric acid, and histamine [ 21 , 28 , 29 ].…”

Section: Microbiome and Mucosal Immunitymentioning

confidence: 99%

Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut–Lung Axis: Future Possibilities for SARS-CoV-2 Protection

Pereira

Kang

et al. 2022

BioTech

View full text Add to dashboard Cite

Infectious diseases caused by mucosal pathogens significantly increase mortality and morbidity. Thus, the possibility to target these pathogens at their primary entry points can consolidate protective immunity. Regarding SARS-CoV-2 infection, it has been observed that the upper respiratory mucosa is highly affected and that dysregulation of resident microbiota in the gut–lung axis plays a crucial role in determining symptom severity. Thus, understanding the possibility of eliciting various mucosal and adaptive immune responses allows us to effectively design bacterial mucosal vaccine vectors. Such design requires rationally selecting resident bacterial candidates as potential host carriers, evaluating effective carrier proteins for stimulating an immune response, and combining these two to improve antigenic display and immunogenicity. This review investigated mucosal vaccine vectors from 2015 to present, where a few have started to utilize Salmonella and lactic acid bacteria (LAB) to display SARS-CoV-2 Spike S proteins or fragments. Although current literature is still lacking for its studies beyond in vitro or in vivo efficiency, decades of research into these vectors show promising results. Here, we discuss the mucosal immune systems focusing on the gut–lung axis microbiome and offer new insight into the potential use of alpha streptococci in the upper respiratory tract as a vaccine carrier.

show abstract

Interkingdom Communication and Regulation of Mucosal Immunity by the Microbiome

Cited by 15 publications

References 38 publications

Role of mucositis in predicting gut microbiota composition in people with cancer

Role of mucositis in predicting gut microbiota composition in people with cancer

Exploring Functional Products and Early-Life Dynamics of Gut Microbiota

Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut–Lung Axis: Future Possibilities for SARS-CoV-2 Protection

Contact Info

Product

Resources

About